Haploinsufficiency of 8p22 may influence cancer-specific survival in prostate cancer

被引:3
作者
Matsuyama, Hideyasu
Oba, Kazuo
Matsuda, Kenji
Yoshihiro, Satoru
Tsukamoto, Manabu
Kinjo, Mitsuru
Sagiyama, Kazuyuki
Takei, Mineo
Yamaguchi, Akito
Sasaki, Kohsuke
Naito, Katsusuke
机构
[1] Yamaguchi Univ, Sch Med, Dept Urol, Ube, Yamaguchi 7558505, Japan
[2] Nippon Steel Mem Yahata Hosp, Dept Pathol, Kitakyushu, Fukuoka, Japan
[3] Sagiyama Urol Clin, Fukuoka, Japan
[4] Hara Sanshinkai Hosp, Dept Urol, Fukuoka, Japan
[5] Yamaguchi Univ, Sch Med, Dept Pathol, Ube, Yamaguchi 755, Japan
基金
日本学术振兴会;
关键词
D O I
10.1016/j.cancergencyto.2006.11.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although Knudson's two-hit hypothesis with functional loss of a tumor suppressor gene has been widely accepted, accumulating evidence suggests that several genes are regulated by the quantity of their product in a dose-dependent manner (gene dosage effect). The study was designed to identify the influence of gene dosage effect of 8p22 on patient prognosis. With a median age of 71 years, 40 patients with prostate cancer (11 organ-confined, 13 capsular penetrating, and 16 nodal and/or distant metastatic) were followed for a median of 68.5 months. A fluorescence in situ hybridization (FISH) technique was applied using a region-specific cosmid probe combined with centromeric probe. Allelic losses of 8p22, 8p21.3, 8p21.1-2, and 8p12 were found in 23, 22, 14, and 9 patients, respectively. A Cox proportional hazard model revealed that decreased fraction (i.e., the fraction of nuclei with a lesser number of cosmid signals than of centromeric probe signals) of 8p22 proved to be the sole independent prognostic factor predicting cancer-specific death, as well as disease progression-but allelic loss of 8p22 was not predictive. Cytogenetic estimation of 8p22 by FISH can yield quantitative evaluation of relevant gene dosage, which may become a useful biomolecular marker predicting poor patient prognosis. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:24 / 34
页数:11
相关论文
共 41 条
[31]  
MOSTOFI FK, 1980, WHO INT HISTOLOGICAL
[32]   Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer [J].
Oba, K ;
Matsuyama, H ;
Yoshihiro, S ;
Kishi, F ;
Takahashi, M ;
Tsukamoto, M ;
Kinjo, M ;
Sagiyama, K ;
Naito, K .
CANCER GENETICS AND CYTOGENETICS, 2001, 124 (01) :20-26
[33]   Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium [J].
Ornstein, DK ;
Cinquanta, M ;
Weiler, S ;
Duray, PH ;
Emmert-Buck, MR ;
Vocke, CD ;
Linehan, WM ;
Ferretti, JA .
JOURNAL OF UROLOGY, 2001, 165 (04) :1329-1334
[34]   Natural history of progression after PSA elevation following radical prostatectomy [J].
Pound, CR ;
Partin, AW ;
Eisenberger, MA ;
Chan, DW ;
Pearson, JD ;
Walsh, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1591-1597
[35]   Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma [J].
Sato, K ;
Qian, JQ ;
Slezak, JM ;
Lieber, MM ;
Bostwick, DG ;
Bergstralh, EJ ;
Jenkins, RB .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) :1574-1580
[36]   Prostate-specific antigen after radiation therapy - Prognosis by pretreatment level and post-treatment nadir [J].
Schellhammer, PF ;
ElMahdi, AM ;
Kuban, DA ;
Wright, GL .
UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :407-+
[37]  
SOBIN LH, 1997, TNM CLASSIFICATION M, P165
[38]  
STRACHAN T, 2004, HUM MOL GENET, V3, P462
[39]  
TAKAHASHI S, 1994, CANCER RES, V54, P3574
[40]  
VISAKORPI T, 1995, CANCER RES, V55, P342